Imlygic
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.imlygic.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Imlygic
Amgen, Inc. offers IMLYGIC® (talimogene laherparepvec), a prescription medication designed to treat melanoma, a type of skin cancer that cannot be surgically removed. This innovative therapy is the first FDA-approved viral treatment that is injected directly into melanoma tumors, aiming to destroy cancer cells. IMLYGIC is intended for patients with advanced melanoma and is administered by healthcare professionals. The company provides resources and support for both patients and healthcare providers regarding the use and safety of IMLYGIC.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imlygic your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Imlygic had a recent Job posting/layoffs
Imlygic, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Imlygic launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Imlygic has new funding data
Check if Imlygic has recently received funding, and reach out quickly before it becomes old news!
Check out if Imlygic is spiking on competitors!
Earning: See what the market has to say on Imlygic recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Imlygic
Recommended Actions
Find VP level buyers at Imlygic
Find 2 more new buyers
Compare Similar Companies to Imlygic
Compare insights from companies similar to Imlygic, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Imlygic
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Imlygic is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Imlygic is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Imlygic.
Imlygic Tech Stack
A closer look at the technologies used by Imlygic
Imlygic News & Media
Amgen Presents First Clinical Data for AMG 757 at SITC 2020
THOUSAND OAKS, Calif., Nov. 9, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the first presentation of AMG 757 Phase 1 clinical safety and efficacy data in relapsed or refractory small cell lung cancer (SCLC). AMG 757 is an investigational half-life extended (HLE) bispecific T...Amgen Showcases Oncology Pipeline At ASCO 2020
THOUSAND OAKS, Calif., May 13, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that data from its oncology pipeline and marketed portfolio will be presented during the ASCO20 Virtual Scientific Program taking place May 29 - 31, 2020. Notable data from the oncology pipeline...Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019
THOUSAND OAKS, Calif., Sept. 17, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its oncology pipeline and marketed product portfolio will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, Sept. 27-Oct. 1, 2019....
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Imlygic
Sign Up For FreeTo access detailed company insights
Amgen, Inc. offers IMLYGIC® (talimogene laherparepvec), a prescription medication designed to treat melanoma, a type of skin cancer that cannot be surgically removed. This innovative therapy is the first FDA-approved viral treatment that is injected directly into melanoma tumors, aiming to destroy cancer cells. IMLYGIC is intended for patients with... Read More
